Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Грюненталь ГмбхfiledCriticalГрюненталь Гмбх
Priority claimed from PCT/EP2017/070396external-prioritypatent/WO2018029327A1/en
Publication of EA201990464A1publicationCriticalpatent/EA201990464A1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Данное изобретение относится к фармацевтической лекарственной форме, имеющей прочность при разрушении по меньшей мере 300 Н и содержащей эфедриновый компонент, выбранный из группы, состоящей из эфедрина, псевдоэфедрина и их физиологически приемлемых солей, при этом массовое содержание эфедринового компонента составляет от 0,1 до 60 мас.% относительно общей массы фармацевтической лекарственной формы.This invention relates to a pharmaceutical dosage form having a fracture toughness of at least 300 N and containing an ephedrine component selected from the group consisting of ephedrine, pseudoephedrine and their physiologically acceptable salts, wherein the mass content of the ephedrine component is from 0.1 to 60 wt.% relative to the total weight of the pharmaceutical dosage form.
EA201990464A2017-05-302017-08-11
MEDICINAL FORM OF EPHEDRINE AND ITS DERIVATIVES WITH PROTECTION AGAINST UNAUTHORIZED USE
EA201990464A1
(en)
medicament and pharmaceutical composition for the prevention or treatment of trigeminal neuralgia, method for preventing or treating trigeminal neuralgia in an individual, and use of a carbamate compound.